Ardian has announced the acquisition of a majority stake in GBA Group, partnering with the existing management team and Quadriga Capital. This transaction follows a period of significant growth under the previous ownership, during which the target successfully institutionalized its platform and expanded its geographic reach through targeted acquisitions. The strategic rationale for the new partnership is to further accelerate the target,s international buy,and,build strategy, leveraging the acquirer,s extensive network in the TIC sector. The investment will focus on enhancing the company,s core business, expanding into new high,growth markets, and maintaining a commitment to operational excellence. By combining the target,s scientific expertise with the acquirer,s financial strength and global reach, the group aims to solidify its competitive position as a leading bioanalytical service provider in Europe, focusing on the highly resilient food and pharmaceutical end markets.

GBA Group is a prominent independent provider of bioanalytical laboratory services operating primarily across the DACH region, with a growing presence in Belgium and Poland. The company’s business model is centered on high,stakes testing and analysis for the food, beverage, pharmaceutical, and environmental sectors. By providing a comprehensive and differentiated portfolio of scientific tests, GBA helps its clients ensure product safety and regulatory compliance in highly resilient and non,cyclical markets. The firm operates through an institutionalized platform comprising a vast network of laboratories and specialized sites, supported by a large team of scientific professionals. Its value proposition is defined by leading edge innovation and a high level of customer loyalty, positioning the group as a critical technical partner for safety and quality assurance in essential consumer and healthcare supply chains.